The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
Authors:
- Sarah BrownSBSarah Brown
- On Behalf Of The Myeloma Uk Clinical Trials NetworkONOn Behalf Of The Myeloma Uk Clinical Trials Network
- Samantha HinsleySHSamantha Hinsley
- Mónica BallesterosMBMónica Ballesteros
- Sue BourneSBSue Bourne
- Paul McGarryPMPaul McGarry
- Debbie SherrattDSDebbie Sherratt
- Louise FlanaganLFLouise Flanagan
- Walter GregoryWGWalter Gregory
- Jamie CavenaghJCJamie Cavenagh
- Roger OwenRORoger Owen
- Cathy WilliamsCWCathy Williams
Open Access
- 17 May 2016
- journal article
- research article
- Published by Springer Nature in BMC Hematology
- Vol. 16 (1) , 14
Abstract
Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately 40–50 per million i.e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib (Velcade®) and dexamethasone (CVD) is an effective regimen at relapse and has emerged in recent years as the standard therapy at first relapse in the UK. Carfilzomib has good activity as a single agent in the relapsed setting, and it is expected that efficacy will be improved when used in combination with dexamethasone and cyclophosphamide. MUK Five is a phase II open label, randomised, controlled, parallel group, multi-centre trial that will compare the activity of carfilzomib, cyclophosphamide and dexamethasone (CCD) with that of CVD, given over an equivalent treatment period (24 weeks), in participants with multiple myeloma at first relapse, or refractory to no more than 1 line of treatment. In addition, the study also aims to assess the utility of a maintenance schedule of carfilzomib in these participants. The primary objective of the trial is to assess whether CCD provides non-inferior activity in terms of ≥ VGPR rates at 24 weeks, and whether the addition of maintenance treatment with carfilzomib to CCD provides superior activity in terms of progression-free survival, as compared to CCD with no maintenance. Secondary objectives include comparing toxicity profiles, further summarizing and comparing the activity of the different treatment arms and analysis of the effect of each treatment arm on minimal residual disease status. The development of carfilzomib offers the opportunity to further explore the anti-tumour efficacy of proteasome inhibition and, based on the available evidence, it is important and timely to obtain data on the activity, toxicity and tolerability of this drug. In contrast to ongoing phase III trials, this phase II trial has a unique subset of participants diagnosed with multiple myeloma at first relapse or refractory to no more than 1 line of treatment and will also evaluate the utility of maintenance with carfilzomib for up to 18 months and investigate minimal residual disease status to provide information on depth of response and the prognostic impact thereof. The trial is registered under ISRCTN17354232 , December 2012.Keywords
This publication has 19 references indexed in Scilit:
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studyBlood, 2014
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaBlood, 2013
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia, 2013
- An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2012
- Aortic annulus dimension assessment by computed tomography for transcatheter aortic valve implantation: differences between systole and diastoleThe International Journal of Cardiovascular Imaging, 2012
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyThe Lancet Oncology, 2011
- Emerging therapies for the treatment of relapsed or refractory multiple myelomaEuropean Journal of Haematology, 2010
- DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myelomaAnnals of Hematology, 2009
- The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)Haematologica, 2007
- Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myelomaBritish Journal of Haematology, 2007